These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924 [TBL] [Abstract][Full Text] [Related]
6. A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Kulkarni GS; Lilge L; Nesbitt M; Dumoulin-White RJ; Mandel A; Jewett MAS Eur Urol Open Sci; 2022 Jul; 41():105-111. PubMed ID: 35813250 [TBL] [Abstract][Full Text] [Related]
7. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476 [TBL] [Abstract][Full Text] [Related]
8. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer. Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK. Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006 [TBL] [Abstract][Full Text] [Related]
10. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". Grimm MO; van der Heijden AG; Colombel M; Muilwijk T; Martínez-Piñeiro L; Babjuk MM; Türkeri LN; Palou J; Patel A; Bjartell AS; Caris C; Schipper RG; Witjes WPJ; Eur Urol; 2020 Nov; 78(5):690-698. PubMed ID: 32446864 [TBL] [Abstract][Full Text] [Related]
11. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457 [TBL] [Abstract][Full Text] [Related]
12. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291 [TBL] [Abstract][Full Text] [Related]
13. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502 [TBL] [Abstract][Full Text] [Related]
14. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. Tan WS; Panchal A; Buckley L; Devall AJ; Loubière LS; Pope AM; Feneley MR; Cresswell J; Issa R; Mostafid H; Madaan S; Bhatt R; McGrath J; Sangar V; Griffiths TRL; Page T; Hodgson D; Datta SN; Billingham LJ; Kelly JD Eur Urol; 2019 Jan; 75(1):63-71. PubMed ID: 30274699 [TBL] [Abstract][Full Text] [Related]
15. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy. Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346 [TBL] [Abstract][Full Text] [Related]
16. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Shepherd AR; Shepherd E; Brook NR Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259 [TBL] [Abstract][Full Text] [Related]
17. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy. Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518 [TBL] [Abstract][Full Text] [Related]
18. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Contieri R; Hensley PJ; Tan WS; Grajales V; Bree K; Nogueras-Gonzalez GM; Lee BH; Navai N; Dinney CP; Kamat AM Eur Urol Oncol; 2023 Dec; 6(6):590-596. PubMed ID: 37558542 [TBL] [Abstract][Full Text] [Related]
19. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. Packiam VT; Lamm DL; Barocas DA; Trainer A; Fand B; Davis RL; Clark W; Kroeger M; Dumbadze I; Chamie K; Kader AK; Curran D; Gutheil J; Kuan A; Yeung AW; Steinberg GD Urol Oncol; 2018 Oct; 36(10):440-447. PubMed ID: 28755959 [TBL] [Abstract][Full Text] [Related]
20. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]